Stay updated on Efficacy & Safety of M2951 in Relapsing MS Clinical Trial

Sign up to get notified when there's something new on the Efficacy & Safety of M2951 in Relapsing MS Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Efficacy & Safety of M2951 in Relapsing MS Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed from the content. Additionally, a significant note regarding the modernization of ClinicalTrials.gov data ingest scheduled for July 2025 has been deleted.
    Difference
    0.5%
    Check dated 2025-07-04T04:19:48.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    19 days ago
    Change Detected
    Summary
    The expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.
    Difference
    0.4%
    Check dated 2025-06-19T19:59:50.000Z thumbnail image
  4. Check
    26 days ago
    No Change Detected
  5. Check
    33 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.1 to version 2.16.2.
    Difference
    0.0%
    Check dated 2025-06-05T11:26:29.000Z thumbnail image
  6. Check
    41 days ago
    Change Detected
    Summary
    The web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.
    Difference
    0.7%
    Check dated 2025-05-29T06:14:15.000Z thumbnail image
  7. Check
    48 days ago
    Change Detected
    Summary
    The page has removed the phrase 'Last Update Posted (Estimated)' and replaced it with 'Last Update Posted'.
    Difference
    0.0%
    Check dated 2025-05-22T03:57:08.000Z thumbnail image
  8. Check
    55 days ago
    Change Detected
    Summary
    The web page has been updated to include new data on the administration and assessment of Evobrutinib and Tecfidera in clinical trials, with specific details on dosages, treatment periods, and assessment metrics. Additionally, there are updates to the publication dates and references related to the studies.
    Difference
    33%
    Check dated 2025-05-15T00:00:13.000Z thumbnail image

Stay in the know with updates to Efficacy & Safety of M2951 in Relapsing MS Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Efficacy & Safety of M2951 in Relapsing MS Clinical Trial page.